Previous research has shown that as much as 20% to 30% of hepatitis C patients receiving antiviral treatment experience major
depression, which can result in dose reductions and a shorter duration of
treatment. The need to identify patients at risk is therefore exceptionally pressing, according to the study's lead author, Muhamad Aly Rifai, MD, from the Lehigh Valley Health Network in Bethlehem, Pennsylvania.